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Introduction
Permanent cessation of menstruation at menopause due to 
reduced or lost ovarian activity and provision of the oestro-
gen hormone will lead in the long run to faster rate of bone 
resorption than formation and increasing risk of osteoporo-
sis.1–3 This metabolic bone disease is marked by reduction in 
bone mass density (BMD), deterioration of bone microarchi-
tecture and increased bone fragility. The incidence of osteo-
porosis increases with age and time after menopause, and at 
a typical level of about 15%–40% remains a major hazard 
for ageing postmenopausal women practically everywhere in 
the world.4–6
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Abstract
Objectives: Osteoporosis is a metabolic bone disease of reduced bone mass density (BMD) and elevated risk of fracture 
due to an imbalance in bone formation and resorption. The risk and incidence of osteoporosis increase towards advanced 
age, particularly in postmenopausal women, and the risk is known to be affected by the variation in the expression of the 
associated regulatory genes. This work aimed to clarify the impact of variation in RUNX2 (runt domain transcription factor 
2), which is an osteoblast-specific transcription factor that normally stimulates bone formation and osteoblast differentiation, 
regarding single-nucleotide polymorphism within RUNX2 promoter (P1) and risk of osteoporosis in postmenopausal 
Indonesian women.
Methods: Using DNA sampling from blood, the variation at the single-nucleotide polymorphism (-330, G→T, rs59983488) 
at the RUNX2 P1 promoter was investigated using polymerase chain reaction–restriction fragment length polymorphism for 
180 consenting postmenopausal Indonesian women. The subjects were examined for bone mass density and classification to 
normal and those with osteopenia or osteoporosis by T-scoring with dual-energy X-ray absorptiometry. Chi-square testing 
and logistic regression were mainly used for statistical assessment.
Results: The results showed a general trend with increased risk of osteoporosis associated with the genotype TT (mutant 
type) and the corresponding T allele of the tested polymorphism of RUNX2 promoter P1. The trend was, however, not 
significant in multivariate testing adjusted for age and time after menopause.
Conclusion: To confirm the potential risk with TT genotype would require testing of a much larger sample of subjects. As 
the tested single-nucleotide polymorphism only represents one of the relevant candidate locations of RUNX2, the results are 
taken nevertheless to suggest an impact by overall RUNX2 variation in the risk of osteoporosis in Indonesian postmenopausal 
women.
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While a combination of environmental and genetic fac-
tors will affect bone strength, genetic ones are implicated by 
twin and family studies to account for more than 50% of the 
variance in BMD.6 The variation implies corresponding 
shifts in the network of regulatory genes responsible for the 
action balance between the osteoblastic bone formation and 
osteoclastic bone resorption. One of the genes involved in 
bone formation is RUNX2 residing at the chromosomal loca-
tion 6p21, spanning 124.7 kb and containing two promoters 
P1 and P2, and seven exons. The promoters result in two 
expressed isoforms of RUNX2 (runt domain transcription 
factor 2), of which RUNX2-I driven by P2 contains 514 
amino acid residues, and RUNX2-II driven by P1 contains 
528 residues. Both isoforms are found in human osteoblast 
cells and osteoblast precursors and are important for osteo-
blast differentiation and bone remodelling. Several other 
genes encoding bone matrix require RUNX2 expression, 
including those expressing alkaline phosphatase, osteopon-
tin, bone sialoprotein and COL1A1.5–7 Mice deficient of the 
transcription factor RUNX2 do not show complete bone for-
mation, and heterozygous RUNX2 knockout mice show 
abnormalities characteristic of cleidocranial dysplasia 
(CCD).8 Some mutations in RUNX2 can disrupt the DNA-
binding activity of the transcription factor, while others can 
have more subtle impact on the RUNX2 biological activity 
that is generally complex and apparently not fully clarified 
as yet.
Population studies of polymorphisms of RUNX2 have 
also been carried out and some show association with BMD 
in postmenopausal women.9–11 Polymorphism in the pro-
moter 1 (P1) of RUNX2 at -330 (G→T, rs59983488) single-
nucleotide polymorphism (SNP) position has not been often 
analysed, but the study by Napierala et al.8 suggests an asso-
ciation with human CCD disease. The SNP of P1 (-330) 
upstream of the promoter region at the enhancer elements 
may affect transcription by stimulating the expression of 
RUNX2 through protein attached to the elements. Note that 
this SNP location is specific to humans and does not exist in 
mice.
To intervene the processes leading to osteoporosis, the 
most common approach is to inhibit some essential steps to 
osteoclast formation or activation.4,5 However, another or 
parallel approach could be to promote osteoblasts and osteo-
blastic bone formation, and in this respect, the roles of 
RUNX2 could have potential therapeutic value. On the other 
hand, recent work points towards the involvement of RUNX2 
also in osteoclast activation and therefore to more complex, 
as yet unknown, detailed roles of RUNX2 in the balance of 
bone formation and resorption.12 Considering the large 
impact of osteoporosis hazard in the society, it is, hence, of 
considerable interest to clarify the regulatory role of RUNX2 
and its genetic variation in more detail. This study aimed to 
investigate the association of a selected polymorphism of 
RUNX2 promoter (P1) with BMD and risk of osteoporosis in 
postmenopausal Indonesian women.
Methods
Study subjects, BMD assessment and ethical 
approval
In total, 180 postmenopausal Indonesian women were 
included after obtaining written informed consent signed by 
each participant. Confirmation of the menopausal status was 
based on subject interviews and correlating other data. No 
cases of surgical menopause or subjects on drugs affecting 
bone mass were included. Calcaneous BMD was assessed 
using dual-energy X-ray absorptiometry (DXA), and the 
results were classified in a conventional manner using 
T-score, which is the number of standard deviations (SD) 
below the mean level of young adults. At values above −1, 
T-score is categorised to the normal range, between −1 and 
−2.5 to osteopenia, and below −2.5 to osteoporosis. On this 
basis, 31 of the subjects were diagnosed with osteoporosis, 
112 with osteopenia and 37 as normal (healthy). The study 
and applied methods were approved by the ethical commit-
tee of the Faculty of Dentistry, University of Indonesia.
Sampling and isolation of DNA
Venous blood samples of 2 mL were taken from each subject. 
For DNA isolation, blood samples were inserted into Falcon 
tubes containing red blood cell anticoagulant (1:3), and the 
tube was repeatedly inverted for 10 min. The tubes were then 
centrifuged for 15 min at 1500 rpm at room temperature, 
supernatant was discarded, and this was repeated 3 times. 
After that 2 mL of cell lysis solution (CLS) was added to the 
pellet and the solution in the up-down with the transfer 
pipette, and incubated in a water bath at 37°C for 60 min. 
Protein precipitation (PP) solution of 1.3 mL was added into 
the tube, vortexed and centrifuged at 40°C/3000 rpm for 5 
min. The supernatant was poured into a new tube containing 
2.3 mL of cold isopropanol, and the tube was inverted repeat-
edly until DNA in it appeared white. Then, 1.3 mL of cold 
70% ethanol was added for DNA precipitation, removed and 
dried by inverting the tube. Washing was repeated two times. 
Furthermore, the tube was dried in tilted position. Then, 0.3 
mL of Tris-EDTA buffer (TE) was added (adjusted by the 
amount of DNA) and incubated in a water bath at 37°C for 2 
h. Finally, the solution was transferred into Eppendorf tubes 
with a micropipette (300 µL) and stored at −20°C.
Polymerase chain reaction amplification, 
restriction fragment length polymorphism and 
DNA sequencing
To assess the selected polymorphism in the RUNX2 promoter 
(P1), polymerase chain reaction (PCR) amplification was 
performed using a primer pair that includes the promoter P1. 
At position -330, forward primer 5′-AAA GCA AAG GAG 
GTT GAC CGG-3′ and reverse primer 5′-CCC TGC CCT 
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TCT TTC TCT CTC-3′were used. PCR amplification was 
conducted in Elmer GeneAmp PCR System 9700. The 25 µL 
volume of each reagent consisted of 5 µL of genomic DNA 
and buffer solution containing 0.2 µM of each deoxyribonu-
cleotide triphosphate (dNTP), 0.4 µM of each primer, 0.7U 
Taq polymerase (Promega), 1.5 mM MgCl2 and ddH2O. The 
PCR amplification included 35 cycles with an initial pre-
denaturation at 94°C for 6 min, then the first cycle of dena-
turation at 94°C for 1 min, annealing at 62°C for 30 s and 
elongation at 72°C for 30 s. The final extension was done at 
72°C for 5 min. The amplified fragments were separated by 
electrophoresis on 1.5% agarose gel (Promega) containing 
ethidium bromide 0.5 mg/mL in 1X Tris–acetate–EDTA 
(TAE) buffer solution (0.04 M Tris–acetate, 0.002 M ethylen-
ediaminetetraacetic acid (EDTA), pH 8.0), applying 80V for 
40 min. The length of the amplified target fragment is 225 bp.
Restriction fragment length polymorphism (RFLP) anal-
ysis was performed by inserting the restriction enzyme 
BsaJI (New England Biolabs (NEB), 1 µL, 10U/µL) into a 
tube containing the amplified DNA fragments, 2 µL RE10X 
buffer solution and 18 µL ddH2O. The mixture was incu-
bated in a water bath at 60°C for 4 h, then inactivated by 
incubating at 80°C for 20 min. DNA fragments were sub-
jected to electrophoresis on 3% agarose gel in 1X TAE at 
90V for 60 min. In case of GG genotype (wild), cutting 
with the restriction enzyme resulted in two DNA bands of 
205 bp and 20 bp in size. At the cutting site, mutant type 
will change from G to T, and GT (heterozygous) type is 
represented by three bands of 225 bp, 205 bp and 20 bp, 
and TT type is represented by one 225-bp band. DNA 
sequencing was used to confirm the position of nucleotide 
base changes by the cutting enzyme. DNA sequencing was 
performed by 1st BASE in Singapore to confirm polymor-
phic sites, using the PCR amplicons. The sequencing pro-
cedure involved PCR product purification, sequencing, 
precipitation, re-cycle sequencing and sequence analysis of 
the nucleotide bases.
Statistical analysis
To compare T-scores and grouping to normal subjects and 
those with osteopenia and osteoporosis according to geno-
types and allotypes of the tested polymorphism of RUNX2, 
chi-square or Kruskal–Wallis tests were used for statistical 
analysis. Logistic regression was applied to assess the asso-
ciation of polymorphism and risk of osteoporosis. Statistical 
significance was assumed at p < 0.05.
Results
PCR-amplified DNA samples of the targeted RUNX2 P1 pro-
moter region (-330) was shown to provide in electrophoresis 
the expected single band 225 bp in size (Figure 1(a)). After 
using the cutting enzyme BsaJI for polymorphism status, the 
resulting variants were GG genotype (wild type) with two 
bands, GT genotype (heterozygous) with three bands, and 
TT genotype (mutant) with a single band (Figure 1(b); note 
that in electrophoresis, the smallest fragments of 20 bp in 
size migrated out and are not shown). Example results of 
genotype sequencing for wild-type, heterozygous and mutant 
samples are shown in Figure 2. The mean T-scores and cor-
responding frequencies of normal subjects and those with 
osteopenia and osteoporosis according to genotype and allo-
type of the tested RUNX2 gene promoter polymorphism are 
shown in Table 1. The T-scores were similar for the GG and 
GT genotypes but significantly reduced for the TT genotype. 
From normal subjects to those with osteopenia and osteopo-
rosis, there is a general trend of decreasing percentage in 
case of GG and GT genotypes, and a corresponding but 
stronger increase for the genotype TT. This was also reflected 
in the decrease in the percentages for allotype (allele) G and 
increase in the percentages for allotype (allele) T, as seen in 
Table 1.
Logarithmic regression for comparison of the genotypes 
in the case of combined osteoporosis/osteopenia group gave 
Figure 1. Results of PCR-RFLP: (a) PCR-amplified target fragment – M = 100-bp marker ladder; well 1 = negative control; 2 = positive 
control (GADPH primer); 3–5 = samples with 225-bp PCR product and (b) fragments after BsaJI enzyme cutting – M = 50-bp marker 
ladder, wells 1 and 4 = GG; 2–3 = GT; 5 = TT.
PCR-RFLP: polymerase chain reaction–restriction fragment length polymorphism; PCR: polymerase chain reaction; GADPH: glyceraldehyde 3-phosphate 
dehydrogenase.
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a slightly elevated odds ratio (OR) of 2.39 (95% CI: 0.73–
7.87) for the TT genotype in comparison with the wild type 
(GG), which is not statistically significant when the data are 
adjusted for age and time after menopause (p = 0.147).
Figure 2. The results of sequencing: (a) = homozygous wild type (GG); (b) = homozygous mutant (TT); (c) = heterozygous (GT).
Table 1. Frequency of genotypes and allotypes related to T-scores and grouping to normal subjects and those with osteopenia or 
osteoporosis; the p-values of 0.245 and 0.094 refer to comparison between normal and osteopenia/osteoporosis groups.
Genotype Allele
 GG GT TT p G T p
Total N (%) 110 (61.1) 42 (23.3) 28 (15.6) 262 (72.8) 98 (27.2) <0.001a
Age, mean (SD) 53.2 (5.1) 53.4 (4.3) 54.3 (4.7) – – –
T-score, mean (SD) −1.42 (0.99) −1.38 (0.80) −1.85 (0.74) 0.007 – – –
Normal N (%) 25 (67.6) 10 (27.0) 2 (5.4) 60 (81.1) 14 (18.9)  
Osteopenia N (%) 68 (60.7) 26 (23.2) 18 (16.1) 0.245 162 (72.3) 62 (27.7) 0.094
Osteoporosis N (%) 17 (54.8) 6 (19.4) 8 (25.8) 40 (64.5) 22 (35.5)  
SD: standard deviation; HWE: Hardy-Weinberg equilibrium.
aRegarding HWE.
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Discussion
The genotype/allotype frequency distributions in this work 
deviated significantly from the Hardy–Weinberg equilib-
rium (p < 0.001). The reasons are not clear but disequilib-
rium appears not to be exceptional for RUNX2 
polymorphisms.10 The mean T-scores of the GG and GT 
genotypes of the tested polymorphism were similar, but the 
fraction of subjects representing the GG genotype were 
about twice as common as those of GT genotype in all 
groups from normal (healthy) to osteoporotic (Table 1). In 
contrast, the least common TT genotype showed a signifi-
cantly reduced level of mean T-score (p = 0.007). In case of 
GG and GT genotypes, there was a general trend of lower 
fraction of the subjects appearing in the osteoporosis group 
than in the group with normal range of BMD. In case of TT 
genotype, there was a corresponding, but more pronounced, 
increase of the fraction of subjects in the osteoporosis 
group. As expected, such a systematic trend was also 
reflected in the corresponding differences for allotype 
(allele) G and allotype (allele) T. The indicated risk of oste-
oporosis as OR appears to be elevated for genotype TT, but 
this is not statistically significant when adjusted for age and 
time after menopause. The sample was relatively small, 
comprising of 180 subjects in total, with 28 (15.6%) repre-
senting the TT genotype and only 8 of these with osteopo-
rosis. However, as all observed trends are systematic from 
normal healthy subjects through osteopenia to osteoporo-
sis, it is thought likely that in this case significance can be 
demonstrated by increasing the sample size. Indeed, sev-
eral other studies have used significantly higher number of 
subjects, albeit partly because of lower frequencies of 
mutant genotypes.9–11 However, the results of this work 
also clearly indicate that multiple causes must be involved 
in the observed variation of BMD. This is not surprising as 
even for RUNX2, several different polymorphisms have 
been suggested to partially explain the observed variation 
in the genetic roots of osteoporosis (Table 2), and multiple 
other genes are known to influence the balance of osteo-
blastic bone formation and osteoclastic resorption.6–11
Many of the polymorphisms of RUNX2 studied in the pre-
vious investigations have represented relatively rare mutants 
that as such cannot alone reflect any major fraction of osteo-
porotic cases. In contrast, the polymorphism (-330 G→T) of 
the P1 region of RUNX2 is relatively common, with TT gen-
otype indicated for 15.6% of the subjects in this work. As 
this mutant is common, it is, on the other hand, unlikely that 
it would confer very serious impact on the processes of bone 
formation. In agreement with this view, it has been reported 
that this polymorphism has no effect on the promoter activity 
in vitro.11
As osteoporosis in postmenopausal women is common 
(affecting 17.2% of the subjects on average in this work but 
more with advancing age) and at least by 50% explained by 
genetic factors, variation in individual genes shown by SNPs 
are unlikely to account for very large fraction of the total 
variation in BMD. As seen above, even for genes like RUNX2 
that certainly can carry major influence on the bone homeo-
stasis, the variation associated with individual SNPs is mod-
est and at best can only explain a small part of the risk of 
osteoporosis. A more holistic view may be sought from 
genome-wide SNP analysis, suggesting that most of the 
genetic impact arises from chromosomes 4, 5, 7, 9, 11, 16 
and 22, rather than from chromosome 6, where RUNX2 is 
residing.12
However, expression of individual regulatory genes can 
serve as a very valuable therapeutic target, as has been 
shown, for example, in experiments for receptor activator of 
nuclear factor kappa-B ligand (RANKL) inhibition against 
osteoporosis.5,6 In the case of RANKL, the emphasis is on 
reduction in osteoclastic bone resorption, but another poten-
tially useful option is to promote the counteracting process 
of osteoblastic bone formation through activation of corre-
sponding genes such as RUNX2.13–22 In addition, RUNX2 
has been shown to be involved also in the regulation of the 
osteoclastic side of the balance, and this could lend further 
weight on future development of new agents or targets for 
this purpose. For this purpose, further work is needed to 
clarify the detailed regulatory mechanisms.
Table 2. Examples of tested RUNX2 polymorphisms8–11 (M = male, F = female).
Polymorphism Promoter Subjects (N) Frequency Reference
−336 G→A P1 Scottish (988 F) AA 0.5%, GG 75.6% Vaughan et al.11
−1176 T→C P1 American, 
Canadian, European
Only with CCD Napierala et al.8
−1048 A→C 100 with CCD 1/180 (0.6%)  
−334 C→A (M and F) Only with CCD  
−330 G→T 15/180 (8.3%)  
−1025 T→C P2 Korean (729 F) CC 1.2%, TT 83.7% Lee et al.9
−1492 A→T P2 TT 0%, AA 99.9%  
−1025 T→C P2 Spanish (776 F) CC 0.9%, TT 88.3% Pineda et al.10
−330 G→T P1 Indonesian (180 F) TT 15.6%, GG 61.1% This work
M: male; F: female.
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Conclusion
The results showed a general trend with increased risk of 
osteoporosis associated with the genotype TT (mutant type) 
and the corresponding T allele of the tested polymorphism 
(-330, G→T, rs59983488) of RUNX2 promoter P1 region in 
postmenopausal Indonesian women. The trend was however 
not significant in multivariate testing adjusted for age and 
time after menopause. In spite of the known essential role of 
RUNX2 in activating and mediating osteoblastic bone forma-
tion, the variation corresponding to the tested relatively com-
mon polymorphism can only explain a small fraction of the 
genetic risk of osteoporosis. RUNX2 activity may neverthe-
less provide targets or model sites to promote bone forma-
tion and combat osteoporosis.
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